[Anticonvulsive properties of peptide ACTH4-7 pro-gly-pro detected in amygdaloid kindling and audiogenic epilepsy in rats].
Chepurnov. S A SA; Chepurnova. N E NE; Artiukhova. M V MV; Kuznetsova. E Iu EIu; Nezavibat'ko. V N VN
Key Findings
- ACTH4-7 pro‑gly‑pro reduced after‑discharges in the amygdaloid kindling (a lab seizure model).
- In audiogenic (sound‑induced) epilepsy‑prone rats, the peptide lowered the seizure threshold, meaning seizures started at lower stimulus levels.
- The peptide did not prevent the motor convulsions in the audiogenic epilepsy test.
Practical Outcomes
- The mixed results mean there’s no clear, actionable protocol for using semax as an anti‑seizure or neuroprotective supplement in humans. Biohackers should treat this as early‑stage animal data and wait for more robust human studies before considering dosage or therapeutic use.
Summary
In rats, the peptide ACTH4-7 pro‑gly‑pro (the core of semax) showed some anti‑seizure activity in a lab model where repeated brain stimulation creates seizures, but it actually made seizures happen more easily in a different rat model that is prone to sound‑triggered seizures and didn’t stop the full‑body convulsions.
Abstract
Effects of the ACTH4-7 pro-gly-pro, calcium valproate ("Germed", DDR) and nembutal on kindling preparation and audiogenic epilepsy were investigated. Development of after-discharges in response to repeated amygdaloid electrical stimulation was assessed in normal rats and in rats susceptible to audiogenic epilepsy (KM line of rats). ACTH4-7 pro-gly-pro had an anticonvulsant profile. ACTH4-7 pro-gly-pro decreased seizure threshold in the audiogenic epilepsy test, but did not prevent the motor convulsions.
Study Information
pubmed
1989